# ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

> **NCT05355298** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Amplia Therapeutics Limited** · enrollment: 62 (estimated)

## Conditions studied

- Pancreatic Cancer
- PDAC
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** AMP945 ascending doses
- **DRUG:** AMP945 RP2D

## Key facts

- **NCT ID:** NCT05355298
- **Lead sponsor:** Amplia Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-31
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05355298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05355298, "ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05355298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*